MedTrace Logo

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

NCT03026556 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42534

Last updated 2019-06-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and effectiveness of newly initiated dabigatran among patients diagnosed with non valvular atrial fibrillation (NVAF) in comparison to newly initiated rivaroxaban users and newly initiated apixaban users

Conditions

Interventions

DRUG

Dabigatran vs. Rivaroxaban

observed for 6 years

DRUG

Dabigatran vs. Apixaban

Observed for 6 years

Sponsors & Collaborators

  • Health ResearchTx, LLC (HRTX)

    collaborator UNKNOWN

  • inVentiv Health Clinical (iVH)

    collaborator UNKNOWN

  • United States Department of Defense (DOD)

    collaborator UNKNOWN

  • Boehringer Ingelheim

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-29
Primary Completion
2017-08-23
Completion
2017-08-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03026556 on ClinicalTrials.gov